Daewoong Pharmaceutical Receives Approval for Phase 3 Clinical Trial Plan of COVID-19 Severe Patient Treatment

[Asia Economy Reporter Park Jun-yi] Daewoong Pharmaceutical announced on the 4th that it received approval from the Ministry of Food and Drug Safety for the Phase 3 clinical trial plan of 'DWJ1248,' a treatment for severe COVID-19 patients, on the 31st of last month. Daewoong Pharmaceutical explained, "We will verify the efficacy and safety of DWJ1248 administration in severe COVID-19 patients."

This content was produced with the assistance of AI translation services.